These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 35640077)
1. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077 [TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP; J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465 [TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Giordano SH; Temin S; Chandarlapaty S; Crews JR; Esteva FJ; Kirshner JJ; Krop IE; Levinson J; Lin NU; Modi S; Patt DA; Perlmutter J; Ramakrishna N; Winer EP; Davidson NE J Clin Oncol; 2018 Sep; 36(26):2736-2740. PubMed ID: 29939838 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related]
5. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy? Dempsey N; Sandoval A; Mahtani R Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S Trials; 2020 May; 21(1):391. PubMed ID: 32381018 [TBL] [Abstract][Full Text] [Related]
7. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342 [TBL] [Abstract][Full Text] [Related]
8. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives. Dormann C Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C; Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420 [TBL] [Abstract][Full Text] [Related]
14. A systematic review of dual targeting in HER2-positive breast cancer. Kümler I; Tuxen MK; Nielsen DL Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156 [TBL] [Abstract][Full Text] [Related]
15. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714 [TBL] [Abstract][Full Text] [Related]
16. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714 [TBL] [Abstract][Full Text] [Related]
17. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037 [TBL] [Abstract][Full Text] [Related]
18. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650 [TBL] [Abstract][Full Text] [Related]
19. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277 [TBL] [Abstract][Full Text] [Related]